This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Centre Leon Berard, Centre National De La Recherche Scientifique, National Institute of Health and Medical Research. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 39 
1 out of 5,383 
1 out of 1,853 
Years Active: 2024
Title: The Innovative Contributions of Anna Maria Rita Redavid
Introduction
Anna Maria Rita Redavid is a notable inventor based in Rutigliano, Italy. He has made significant strides in the field of cancer treatment through his innovative research and development of new therapeutic approaches. His work focuses on the intersection of immunology and cancer therapy, particularly through the use of specific compounds that target critical pathways in cancer progression.
Latest Patents
Redavid holds a patent for a groundbreaking invention titled "Combined treatment with Netrin-1 interfering drug and immune checkpoint inhibitors drugs." This invention involves the combination of a compound that disrupts the interaction between netrin-1 and its receptors, known as a NTN1 neutralizing agent, with immune checkpoint inhibitors. The aim is to enhance the efficacy of cancer treatments by utilizing both an anti-netrin-1 antibody and an immune checkpoint inhibitor, which can be administered simultaneously, separately, or sequentially to patients.
Career Highlights
Throughout his career, Redavid has worked with various organizations that focus on advancing medical research and therapeutic development. Notably, he has been associated with Netris Pharma, a company dedicated to innovative cancer therapies, and Université Claude Bernard—Lyon 1, where he has contributed to academic research in the field.
Collaborations
Redavid has collaborated with esteemed colleagues in his field, including Benjamin Ducarouge and David Goldschneider. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his work in cancer treatment.
Conclusion
Anna Maria Rita Redavid's contributions to cancer therapy through his innovative patent demonstrate his commitment to improving patient outcomes. His work exemplifies the potential of combining targeted therapies to create more effective treatment options for cancer patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile